InfuSystem assumed with a Buy at Lake Street

Lake Street assumed coverage of InfuSystem (INFU) with a Buy rating and a price target of $15, up from $12.50. The “leading provider” of infusion pumps and related services, operating under two complementary platforms of Patient Services and Device Solutions, is “laying the groundwork for durable and profitable growth that investors may not fully appreciate today,” the analyst argues.